Date | Price Target | Rating | Analyst |
---|---|---|---|
12/15/2023 | $8.00 | Buy | Citigroup |
4/24/2023 | $9.00 | Buy | H.C. Wainwright |
4/14/2022 | $20.00 | Overweight | Cantor Fitzgerald |
4/8/2022 | $19.00 | Overweight | Piper Sandler |
4/4/2022 | $21.00 | Buy | Citigroup |
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
No Severe Long-Term Toxicities With 2-Year Local Recurrence-Free Survival At 77%
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $8.00
H.C. Wainwright initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $20.00
NEW YORK, NY / ACCESSWIRE / September 17, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day September Small-Cap Conference taking place Wednesday and Thursday, September 18-19, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.Presentation Schedule*All Times EDTWednesday, September 18, 2024 (Day 1)8:30-9:00MtronPTI (MPTI)The Gorman-Rupp Company (GRC)Lilium (LILM)*****9:15-9:45The LGL Group, Inc. (LGL)Natural Gas Services Group (NGS)Harvard Bioscience (HBIO)Lifetime Brands, Inc. (LCUT)10:00-10:30Daktronics (DAKT)Arcosa, Inc (
JERUSALEM, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present a corporate overview and update at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th, 2024 and in the Sidoti Virtual Investor Conference on September 18-19th, 2024 and will participate in the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference on September 26th, 2024 and the Lytham Partners Fall 2024 Investor Conference on October 1st, 2024. Event:H.C. Wainwright 26th Annual Global Investment ConferenceD
- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to-treat superficial cancers, with an overall response rate of almost 100% in treated lesions, no moderate or severe long-term toxicities noted, and a 2-year local recurrence-free survival was estimated at 77% - - Cash, cash equivalents & deposits balance of $74.1 million with runway of at least two years - JERUSALEM, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported seco
JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company's Board of Directors in order to assume the full-time position of Alpha Tau's Chief Commercial Officer. Mr. Melnyk served most recently as CEO of Fortovia Therapeutics, an oncology supportive care pharmaceutical and medical device company headquartered in Raleigh, North Carolina. Before that, he served as Chief Commercial Officer of Novocure, and led the construction of the global commercial platform and infrastructure
JERUSALEM, June 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS) (NASDAQ:DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Mr. Gary Leibler has resigned from the Company's board of directors and its audit committee, for reasons unrelated to the Company. "I wish to thank Gary for his years of dedicated service to the Company, as a member of the board of directors since the early days of Alpha Tau," commented Alpha Tau CEO Uzi Sofer. "He has added tremendous value ever since his first day with us, and we have benefitted greatly from his expertise and experience." Gary Leibler, who also serves as
JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti